Drug
Atabecestat clinical trials
Also written JNJ-54861911.
- studies test it
- 13
- open now
- 0
- in phase 3
- 1
- first study started
- 2013
How studies write it
Studies that test it under each name
Studies by the year they started
13 studies that test it; most in 2013 (4)
| Year | Studies |
|---|---|
| 2013 | 4 |
| 2014 | 3 |
| 2015 | 4 |
| 2016 | 1 |
| 2018 | 1 |
By phase
A phase 1/2 study counts in both.
- Early Phase 1
- 1
- Phase 1
- 9
- Phase 2
- 3
- Phase 3
- 1
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 13 · Other 0
Janssen Research & Development, LLC (11) · Janssen Pharmaceutical K.K. (2)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses atabecestat is read from its arms, and is right about nine times in ten.
Testing it · 13
- A Safety and Tolerability Study of JNJ-54861911 in Participants With Early Alzheimer's DiseaseCompletedPhase 2Janssen Research & Development, LLCNCT02260674Written as JNJ-54861911, 10 milligram (mg)
- An Extension Study to Evaluate the Long-Term Safety and Tolerability of JNJ-54861911 in Participants in the Early Alzheimer's Disease SpectrumTerminatedPhase 2Janssen Research & Development, LLCNCT02406027Written as JNJ-54861911, 10 mg
- An Efficacy and Safety Study of Atabecestat in Participants Who Are Asymptomatic at Risk for Developing Alzheimer's DementiaTerminatedPhase 2/3Janssen Research & Development, LLCNCT02569398Written as Atabecestat, 5 mg
- Characterization of T-Cell Response in Participants Previously Treated With JNJ-54861911 (Atabecestat)CompletedEarly Phase 1Janssen Research & Development, LLCNCT03587376Written as Atabecestat
- A Pharmacokinetic Interaction Study Between JNJ-54861911 and Transporter Substrates Rosuvastatin and Metformin in Healthy ParticipantsCompletedPhase 1Janssen Research & Development, LLCNCT02611518Written as JNJ-54861911
- Study Investigating the Effects of JNJ-54861911 on Amyloid-beta Processing in Cerebrospinal Fluid (CSF) and Plasma in Japanese Participants Asymptomatic at Risk for Alzheimer DementiaCompletedPhase 1Janssen Pharmaceutical K.K.NCT02360657Written as JNJ-54861911, 10 mg
- A Crossover Study to Evaluate the Relative Oral Bioavailability and Food Effect After Single Dose Administration of JNJ-54861911 Tablet in Healthy Elderly ParticipantsCompletedPhase 1Janssen Research & Development, LLCNCT02355561Written as JNJ-54861911 (Treatment A)
- A Study to Assess Effect of JNJ-54861911 on Pharmacokinetics of Cocktail Representatives for Cytochrome P450 (CYP) 3A4, CYP2B6, CYP2C9, and CYP1A2 SubstratesCompletedPhase 1Janssen Research & Development, LLCNCT02211079Written as JNJ-54861911
- A Study to Evaluate the Effects of JNJ-54861911 on Amyloid Beta Processing in Cerebrospinal Fluid and Plasma in Patients With Prodromal Alzheimer's DiseaseCompletedPhase 1Janssen Research & Development, LLCNCT01978548Written as JNJ-54861911 10 mg
- A Study to Investigate the Safety, Tolerability and Pharmacokinetics of JNJ-54861911 in Healthy Volunteers Compared With PlaceboCompletedPhase 1Janssen Research & Development, LLCNCT01827982Written as JNJ-54861911 1mg
- A Study to Evaluate Bioavailability, Food Effect, Safety and Tolerability of a Solid Dosage Formulation of JNJ-54861911 in Healthy Older Male ParticipantsCompletedPhase 1Janssen Research & Development, LLCNCT02260700Written as JNJ-54861911 (Treatment A)
- A Safety, Tolerability and Pharmacokinetics Study of JNJ-54861911 in Healthy Japanese Male ParticipantsCompletedPhase 1Janssen Pharmaceutical K.K.NCT02180269Written as JNJ-54861911 (25 mg)
- A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of JNJ-54861911 in Healthy Elderly ParticipantsCompletedPhase 1Janssen Research & Development, LLCNCT01887535Written as JNJ-54861911 3 mg
Given in every arm · 1 — atabecestat is usual care beside what is tested
Codes
What other systems call atabecestat · ClinicalTrials.gg INT001159
- MeSH (NLM) C000634126atabecestatOne source NLM
- UNII (FDA) 2834W8D6GKATABECESTATConfirmed FDA, NLM
- NCI Thesaurus C166553AtabecestatOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000634126 | atabecestat | One source NLM |
| UNII (FDA) | 2834W8D6GK | ATABECESTAT | Confirmed FDA, NLM |
| NCI Thesaurus | C166553 | Atabecestat | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.